Gilead Sciences, Inc.
GILD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $115 | $101 | $108 | $91 |
| - Cash | $10 | $6 | $5 | $5 |
| + Debt | $27 | $25 | $25 | $27 |
| Enterprise Value | $132 | $120 | $128 | $113 |
| Revenue | $29 | $27 | $27 | $27 |
| % Growth | 6% | -0.6% | -0.1% | – |
| Gross Profit | $23 | $21 | $22 | $21 |
| % Margin | 78.3% | 76% | 79.3% | 75.8% |
| EBITDA | $4 | $10 | $9 | $11 |
| % Margin | 15.4% | 38.7% | 32.4% | 41.5% |
| Net Income | $0 | $6 | $5 | $6 |
| % Margin | 1.7% | 20.9% | 16.8% | 22.8% |
| EPS Diluted | 0.38 | 4.5 | 3.64 | 4.93 |
| % Growth | -91.6% | 23.6% | -26.2% | – |
| Operating Cash Flow | $11 | $8 | $9 | $11 |
| Capital Expenditures | -$1 | -$1 | -$1 | -$1 |
| Free Cash Flow | $10 | $7 | $8 | $11 |